CareDx said on Wednesday that it has priced a planned $125 million public stock offering at $32 per share.

Researchers at Johns Hopkins University have developed a gene editing approach they call very fast CRISPR (vfCRISPR) that is capable of creating double-strand breaks (DSBs) in seconds, and at the submicrometer scale.

Roche subsidiary Foundation Medicine announced Friday it has acquired precision oncology firm Lexent Bio to help expand its liquid biopsy platforms and advance cancer care.

A recent genetic association study of people who are naturally thin has tied variants in the anaplastic lymphoma kinase (ALK) gene to thinness.

Genedrive said Friday that it has received the CE mark for its Genedrive 96 SARS-CoV-2 Kit and is making it available for sale in the European Union, including the UK, and other countries that accept the mark.

P23 Labs has received Emergency Use Authorization for its coronavirus PCR test from the US Food and Drug Administration.

The US Food and Drug Administration on Thursday granted separate Emergency Use Authorizations (EUAs) for PCR-based SARS-CoV-2 tests developed by South Korean diagnostic test makers BioCore, SolGent, and Seasun Biomaterials.

Agilent Technologies reported after the close of the market on Thursday that its second quarter 2020 revenue growth was flat year over year.

The US Food and Drug Administration on Wednesday announced the approval of AstraZeneca and Merck's olaparib (Lynparza) for metastatic castration-resistant prostate cancer patients with homologous recombination repair deficiency.

Proteomics firm Nautilus Biotechnology announced Thursday it has closed an oversubscribed $76 million Series B financing round.

Northern and southern Italian populations began to diverge genetically thousands of years ago, according to a new study.

People in the News: Tony Serafini-Lamanna, Martin Chavez, Sun Kim, Oved Amitay, More

Host factors rather than viral genetic differences appear to influence disease outcomes among COVID-19 patients, according to a new study from China.

Roche said on Friday that it has acquired Seattle-based early-stage sequencing technology firm Stratos Genomics for an undisclosed amount in a bid to advance development of Roche's nanopore sequencer.

Regeneron Pharmaceuticals and the Colorado Center for Personalized Medicine (CCPM) said Monday